New research suggests that individuals who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise programs.
Findings released in a leading health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users buying these drugs need to be informed of the potential of rapid rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment mass within about 18 months.
Weighing Approaches
The analysis, which reviewed dozens of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with older methods.
Scientists note that people who shed pounds through diet and exercise usually experience a slower weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Doctors believe the mode of action of the jabs is key to understanding the accelerated regain.
These medications mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels several times higher than normal might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of weight regain, the therapy might need to be long-term.
This view is echoed by drug manufacturers, who note that the findings "highlight the long-term nature of excess weight," similar to managing conditions like high blood pressure.
User Accounts
Users who have come off the medication report a intense return of appetite.
"I experienced a switch activating and you're instantly ravenous," recalled a patient.
The struggle is worsened if users have not established lasting dietary or behavioural changes during therapy.
Significant Interest
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, experts caution that while the jabs are potent tools for shedding pounds, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural management.
